These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35489754)

  • 1. The
    Han M; Yamaguchi S; Onishi M; Fujii T; Hosoya M; Wen X; Kido H; Kato S
    Anticancer Res; 2022 May; 42(5):2277-2288. PubMed ID: 35489754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
    Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
    Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
    Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
    Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.
    Møller MB; Ino Y; Gerdes AM; Skjødt K; Louis DN; Pedersen NT
    Leukemia; 1999 Mar; 13(3):453-9. PubMed ID: 10086736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.
    Ghimenti C; Fiano V; Chiadò-Piat L; Chiò A; Cavalla P; Schiffer D
    J Neurooncol; 2003 Jan; 61(2):95-102. PubMed ID: 12622447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Liberski PP
    Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 expression and relationship with MDM2 amplification in breast carcinomas.
    Buyukpinarbasili N; Gucin Z; Ersoy YE; İlbak A; Kadioglu H; Muslumanoglu M
    Ann Diagn Pathol; 2016 Apr; 21():29-34. PubMed ID: 27040927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
    Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors.
    Sonkin D
    Elife; 2015 Oct; 4():. PubMed ID: 26491944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
    Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
    Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss.
    Liu S; Wu Y; Yang T; Feng C; Jiang H
    Oncotarget; 2016 Jun; 7(23):34752-8. PubMed ID: 27167196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
    Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
    Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.
    Dreidax D; Gogolin S; Schroeder C; Muth D; Brueckner LM; Hess EM; Zapatka M; Theißen J; Fischer M; Ehemann V; Schwab M; Savelyeva L; Westermann F
    Hum Mol Genet; 2013 May; 22(9):1735-45. PubMed ID: 23343716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
    Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
    Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a novel CNV-related prognostic signature predicting prognosis in patients with breast cancer.
    Hu W; Li M; Zhang Q; Liu C; Wang X; Li J; Qiu S; Li L
    J Ovarian Res; 2021 Aug; 14(1):103. PubMed ID: 34364397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
    Ishizawa J; Nakamaru K; Seki T; Tazaki K; Kojima K; Chachad D; Zhao R; Heese L; Ma W; Ma MCJ; DiNardo C; Pierce S; Patel KP; Tse A; Davis RE; Rao A; Andreeff M
    Cancer Res; 2018 May; 78(10):2721-2731. PubMed ID: 29490944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
    Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Skjønsberg G; Aas T; Schlichting E; Fjösne HE; Nysted A; Lillehaug JR; Lønning PE
    PLoS One; 2011 Apr; 6(4):e19249. PubMed ID: 21556366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.